Yaoxiang Zhu1, Yafang Chen2, Lei Zhu2, Xian Zheng2, Xiaoying Zhou1
1School of Pharmacy, School of Medicine, Changzhou University, Changzhou 213164, Jiangsu, China
2Department of Pharmacy, Affiliated Kunshan Hospital of Jiangsu University, Kunshan 215300, China
Previous research demonstrated that tomato powder presented impressed anti-nonalcoholic fatty liver disease (NAFLD) efficacy through restoring NAMPT/Sirt1 activity. Lycopene, the principal monomer component of tomato powder, also effectively attenuated NAFLD pathological features. However, whether lycopene exerted its beneficial effects via tunning NAMPT/Sirt1 activity is still unknown. To solve this problem, mouse primary hepatocytes were isolated and challenged with palmitate to induce the in vitro model of NAFLD. The cytotoxicity of palmitate and lycopene was tested by MTT assay. Then the “first hit” (i.e., hepatosteatosis) and the “second hit” (i.e., inflammation) parameters were examined following lycopene treatment. Mechanisms involved NAMPT/Sirt1-regulated lipogenesis were determined by western blotting and qRT-PCR. Our results found that lycopene had a high safety profile (no cytotoxicity at 100 μM), while palmitate exhibited potent cytotoxicity (significant cytotoxicity at 0.0625 mM). Finally, we choose 0.5 mM of palmitate and 20, 40 μM of lycopene as the model and intervention conditions, respectively. Under the model condition, lycopene effectively rescued the decrease in cell viability, ameliorate the lipid accumulation, and mitigated the inflammatory response. Further exploration found that activation of NAMPT/Sirt1 and blockage of downstream lipogenesis mediated its favorable effects. In summary, lycopene is sufficient to undo palmitate-induced “two-hit” in primary hepatocytes and is a prospective candidate for NAFLD therapy.
Lycopene, Nonalcoholic fatty liver disease, Two-hit, NAMPT/Sirt1
Yaoxiang Zhu, Yafang Chen, Lei Zhu, Xian Zheng, Xiaoying Zhou. Lycopene counteracts palmitate-induced “two-hit” in mouse primary hepatocytes via triggering NAMPT/Sirt1 pathway. Frontiers in Medical Science Research (2022) Vol. 4, Issue 8: 32-38. https://doi.org/10.25236/FMSR.2022.040807.
 Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016; 64: 73-84.
 Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol. 2009; 24: 248-54.
 Dong R, Yang X, Wang C, et al. Yangonin protects against non-alcoholic fatty liver disease through farnesoid X receptor. Phytomedicine. 2019; 53: 134-42.
 Guo WW, Wang X, Chen XQ, et al. Flavonones from Penthorum chinense Ameliorate Hepatic Steatosis by Activating the SIRT1/AMPK Pathway in HepG2 Cells. Int J Mol Sci. 2018; 19.
 Han X, Cui ZY, Song J, et al. Acanthoic acid modulates lipogenesis in nonalcoholic fatty liver disease via FXR/LXRs-dependent manner. Chem Biol Interact. 2019; 311: 108794.
 Yang J, Fernández-Galilea M, Martínez-Fernández L, et al. Oxidative Stress and Non-Alcoholic Fatty Liver Disease: Effects of Omega-3 Fatty Acid Supplementation. Nutrients. 2019; 11.
 Nassir F, Ibdah JA. Sirtuins and nonalcoholic fatty liver disease. World J Gastroenterol. 2016; 22: 10084-92.
 Kawata A, Murakami Y, Suzuki S, et al. Anti-inflammatory Activity of β-Carotene, Lycopene and Tri-n-butylborane, a Scavenger of Reactive Oxygen Species. In Vivo. 2018; 32: 255-64.
 Ni Y, Zhuge F, Nagashimada M, et al. Lycopene prevents the progression of lipotoxicity-induced nonalcoholic steatohepatitis by decreasing oxidative stress in mice. Free Radic Biol Med. 2020; 152: 571-82.
 Wang J, Suo Y, Zhang J, et al. Lycopene supplementation attenuates western diet-induced body weight gain through increasing the expressions of thermogenic/mitochondrial functional genes and improving insulin resistance in the adipose tissue of obese mice. J Nutr Biochem. 2019; 69: 63-72.
 Zeng Z, He W, Jia Z, et al. Lycopene Improves Insulin Sensitivity through Inhibition of STAT3/Srebp-1c-Mediated Lipid Accumulation and Inflammation in Mice fed a High-Fat Diet. Exp Clin Endocrinol Diabetes. 2017; 125: 610-7.
 Li CC, Liu C, Fu M, et al. Tomato Powder Inhibits Hepatic Steatosis and Inflammation Potentially Through Restoring SIRT1 Activity and Adiponectin Function Independent of Carotenoid Cleavage Enzymes in Mice. Mol Nutr Food Res. 2018; 62: e1700738.
 Salem ESB, Murakami K, Takahashi T, et al. Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method. J Vis Exp. 2018.
 Zheng X, Zhang X-G, Liu Y, et al. Arjunolic acid from Cyclocarya paliurus ameliorates nonalcoholic fatty liver disease in mice via activating Sirt1/AMPK, triggering autophagy and improving gut barrier function. Journal of Functional Foods. 2021; 86: 104686.
 Colak Y, Yesil A, Mutlu HH, et al. A potential treatment of non-alcoholic fatty liver disease with SIRT1 activators. J Gastrointestin Liver Dis. 2014; 23: 311-9.
 Salomone F, Barbagallo I, Godos J, et al. Silibinin Restores NAD⁺ Levels and Induces the SIRT1/AMPK Pathway in Non-Alcoholic Fatty Liver. Nutrients. 2017; 9.
 Chyau CC, Wang HF, Zhang WJ, et al. Antrodan Alleviates High-Fat and High-Fructose Diet-Induced Fatty Liver Disease in C57BL/6 Mice Model via AMPK/Sirt1/SREBP-1c/PPARγ Pathway. Int J Mol Sci. 2020; 21.
 Liu X, Gao Y, Li M, et al. Sirt1 mediates the effect of the heme oxygenase inducer, cobalt protoporphyrin, on ameliorating liver metabolic damage caused by a high-fat diet. J Hepatol. 2015; 63: 713-21.
 Liou CJ, Lee YK, Ting NC, et al. Protective Effects of Licochalcone A Ameliorates Obesity and Non-Alcoholic Fatty Liver Disease Via Promotion of the Sirt-1/AMPK Pathway in Mice Fed a High-Fat Diet. Cells. 2019; 8.
 Tian Y, Ma J, Wang W, et al. Resveratrol supplement inhibited the NF-κB inflammation pathway through activating AMPKα-SIRT1 pathway in mice with fatty liver. Mol Cell Biochem. 2016; 422: 75-84.
 Hua X, Sun DY, Zhang WJ, et al. P7C3-A20 alleviates fatty liver by shaping gut microbiota and inducing FGF21/FGF1, via the AMP-activated protein kinase/CREB regulated transcription coactivator 2 pathway. Br J Pharmacol. 2021; 178: 2111-30.
 Moon YA, Hammer RE, Horton JD. Deletion of ELOVL5 leads to fatty liver through activation of SREBP-1c in mice. J Lipid Res. 2009; 50: 412-23.
 Li CX, Gao JG, Wan XY, et al. Allyl isothiocyanate ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease via the Sirt1/AMPK and NF-κB signaling pathways. World J Gastroenterol. 2019; 25: 5120-33.
 Zheng X, Zhao MG, Jiang CH, et al. Triterpenic acids-enriched fraction from Cyclocarya paliurus attenuates insulin resistance and hepatic steatosis via PI3K/Akt/GSK3β pathway. Phytomedicine. 2020; 66: 153130.
 Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. Embo j. 2004; 23: 2369-80.